Candel Therapeutics $CADL #enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Candel Therapeutics, Inc. is helping pioneer the next generation of viral immunotherapy by leveraging a data-driven approach to create new assets and further the development of existing drug candidates.

Candel Therapeutics' enLIGHTEN Discovery Platform integrates artificial intelligence-selected, therapeutic payloads into programmable vectors for delivery into the tumor microenvironment

This tailored approach to discovery and development of new therapeutics has been designed to address the complexity of the tumor microenvironment and the diversity of the tumor response to existing treatments.